Chronic Itch Pathophysiology and Therapeutic Advances
Day 2 Recap: 2025 Revolutionizing Atopic Dermatitis Conference
Late-Breaking Data: Real-World Registry Data Supports Upadacitinib Efficacy in Moderate to Severe AD, Regardless of Biologic History
Late Breaking Data: Lebrikizumab Demonstrates Efficacy in AD Patients with Skin of Color